感染

订阅

MedSci主页 / 所有栏目 / 感染

F1000推荐和点评上海巴斯德所HIV-1疫苗研发的新突破

2012-08-20 中科院上海巴斯德研究所 中科院上海巴斯德研究所

F1000中科院上海巴斯德研究所HIV-1疫苗
关注

8月13日，Faculty of 1000推荐和点评了中科院上海巴斯德研究所周保罗研究组关于艾滋病病毒I型（HIV-1）疫苗的最新成果论文：HIV-1 Virus-Like Particles Produced by Stably Transfected Drosophila S2 Cells: a Desirable Vaccine Component., Journal of Virology

8月13日，Faculty of 1000推荐和点评了中科院上海巴斯德研究所周保罗研究组关于艾滋病病毒I型（HIV-1）疫苗的最新成果论文：HIV-1 Virus-Like Particles Produced by Stably Transfected Drosophila S2 Cells: a Desirable Vaccine Component., Journal of Virology, 2012 (DOI: 10.3410/f.717952409.793457863)。该论文在世界上首次报道了采用果蝇S2细胞表达系统制备 HIV-1 病毒样颗粒（VLP）作为艾滋病疫苗组分，Faculty of 1000评议成员Luigi Buonaguro和 Maria Tagliamonte认为该研究成果是一种技术上的突破，在领域内具有特殊意义。

意大利国家癌症研究所高级研究员Luigi Buonaguro大概10多年前即开始了HIV 病毒样颗粒（VLP）的研究工作，并于2011年作为通讯作者在《疫苗学》杂志（Vaccine）发表论文HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine. 2011 Jul 12; 29(31): 4913-22。他认为相较于他们之前在昆虫细胞表达产生HIV VLP的方式，周保罗研究组在稳转果蝇S2细胞连续地产生 HIV VLP是一种有很大潜力的新策略；该策略制备产生的带有包膜蛋白的VLP代表了一种用完整构象的HIV抗原来免疫的新方式，该方式虽然还未达到临床试验阶段，却使临床试验的可能性更近了一步。

Faculty of 1000是一种在线“发表后同行评价”系统，该系统聘请国际顶级的生物或医学专家阅读最新发表的文章，请他们本着立足于论文本身的科学意义而非发表在何等杂志上的推荐原则，将该领域全球最好的2%的文章推荐到该系统，并作出评论

链接：

Yang L, Song Y, Li X, Huang X, Liu J, Ding H, Zhu P, Zhou P.HIV-1 Virus-Like Particles Produced by Stably Transfected Drosophila S2 Cells: a Desirable Vaccine Component.J Virol. 2012 Jul;86(14):7662-76

Faculty of 1000的评论

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1724867, encodeId=87531e24867c5, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 31 04:12:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634298, encodeId=e869163429846, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Wed Oct 31 01:12:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947959, encodeId=4dfd194e9599e, content=<a href='/topic/show?id=060fe19851' target=_blank style='color:#2F92EE;'>#F1000#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7198, encryptionId=060fe19851, topicName=F1000)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue May 28 10:12:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4636, encodeId=2b99463633, content=希望早日进入艾滋病可防可治的时代。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ppswppp, createdTime=Thu Aug 23 13:43:00 CST 2012, time=2012-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299727, encodeId=3fec1299e27e5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Aug 22 08:12:00 CST 2012, time=2012-08-22, status=1, ipAttribution=)]
    2013-07-31 zxxiang

    #新突破#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1724867, encodeId=87531e24867c5, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 31 04:12:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634298, encodeId=e869163429846, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Wed Oct 31 01:12:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947959, encodeId=4dfd194e9599e, content=<a href='/topic/show?id=060fe19851' target=_blank style='color:#2F92EE;'>#F1000#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7198, encryptionId=060fe19851, topicName=F1000)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue May 28 10:12:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4636, encodeId=2b99463633, content=希望早日进入艾滋病可防可治的时代。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ppswppp, createdTime=Thu Aug 23 13:43:00 CST 2012, time=2012-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299727, encodeId=3fec1299e27e5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Aug 22 08:12:00 CST 2012, time=2012-08-22, status=1, ipAttribution=)]
    2012-10-31 lilili1111

    #疫苗研发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1724867, encodeId=87531e24867c5, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 31 04:12:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634298, encodeId=e869163429846, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Wed Oct 31 01:12:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947959, encodeId=4dfd194e9599e, content=<a href='/topic/show?id=060fe19851' target=_blank style='color:#2F92EE;'>#F1000#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7198, encryptionId=060fe19851, topicName=F1000)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue May 28 10:12:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4636, encodeId=2b99463633, content=希望早日进入艾滋病可防可治的时代。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ppswppp, createdTime=Thu Aug 23 13:43:00 CST 2012, time=2012-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299727, encodeId=3fec1299e27e5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Aug 22 08:12:00 CST 2012, time=2012-08-22, status=1, ipAttribution=)]
    2013-05-28 ms7019579240139182

    #F1000#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1724867, encodeId=87531e24867c5, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 31 04:12:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634298, encodeId=e869163429846, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Wed Oct 31 01:12:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947959, encodeId=4dfd194e9599e, content=<a href='/topic/show?id=060fe19851' target=_blank style='color:#2F92EE;'>#F1000#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7198, encryptionId=060fe19851, topicName=F1000)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue May 28 10:12:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4636, encodeId=2b99463633, content=希望早日进入艾滋病可防可治的时代。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ppswppp, createdTime=Thu Aug 23 13:43:00 CST 2012, time=2012-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299727, encodeId=3fec1299e27e5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Aug 22 08:12:00 CST 2012, time=2012-08-22, status=1, ipAttribution=)]
    2012-08-23 ppswppp

    希望早日进入艾滋病可防可治的时代。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1724867, encodeId=87531e24867c5, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Jul 31 04:12:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634298, encodeId=e869163429846, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Wed Oct 31 01:12:00 CST 2012, time=2012-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947959, encodeId=4dfd194e9599e, content=<a href='/topic/show?id=060fe19851' target=_blank style='color:#2F92EE;'>#F1000#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7198, encryptionId=060fe19851, topicName=F1000)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Tue May 28 10:12:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4636, encodeId=2b99463633, content=希望早日进入艾滋病可防可治的时代。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ppswppp, createdTime=Thu Aug 23 13:43:00 CST 2012, time=2012-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299727, encodeId=3fec1299e27e5, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Aug 22 08:12:00 CST 2012, time=2012-08-22, status=1, ipAttribution=)]
    2012-08-22 lqvr

    #研发#

    0

相关资讯

F1000微生物学七大新闻(2011.9.22)

嗜肺军团菌，图片来自维基共享资源 1.意外发现新的分子伴侣Spy研究人员在测试基因工程菌大肠杆菌在体内使得不稳定的蛋白质稳定化的能力的过程中，偶然间发现一种新的蛋白分子伴侣Spy，而且该分子伴侣能够抑制蛋白聚集并辅助蛋白重折叠。Spy的塑造不同于其他任何以前研究过的分子伴侣，它能够多达700倍地增加一组不稳定的蛋白突变体的稳态水平。S. Quan et al., “Genetic selec

F1000免疫学七大新闻

急性髓细胞样白血病，图片来自维基共享资源。 1. 阻断表观遗传重编程阻止癌症发生一种调节染色质的蛋白Brd4控制促进急性髓细胞样白血病(acute myeloid leukemia)形成的表观遗传重编程。敲除这种正常条件下上升表达癌基因Myc的蛋白可以选择性地杀死急性髓细胞样白血病细胞，这就提示着治疗这种侵略性疾病有了新的靶标。J. Zuber et al., “RNAi screen id

Lancet：一项多中心、开放的临床随机试验证实微创性食管癌切除术对患者更有益

原文摘要：背景：对于可切除性食管癌而言，外科手术常被认为是唯一的治疗手段，但是开放性食管癌切除术后出现肺部并发症的几率超过半数，这点仍需引起极大关注。因此我们想评估采用微创性食管癌切除术能否减少术后肺部并发症。方法：我们在2009/6/1-2011/3/31期间在三个国家选取了5个医学中心进行了一项多中心、开放标签的随机临床试验。在这个期间被诊断为可切除性食管癌年龄在18-75岁之间的患者被电脑随

F1000生物化学七大新闻 2011.5.23-6.23

一瞥千名科学家(Faculty of 1000)评级最高的生物化学及其相关领域的论文 连接枯草芽胞杆菌和金黄色葡萄球菌的纳米管(图片来自：Figure 6, Cell 44:590-600, 2011) 【towersimper注：本文为译文，有部分改动，仅用作研究之用，不得用作商业开发，转载请标明翻译者towersimper，原文来自 Cristina Luiggi, The Scien